COMPANY PROFILE / #2757
Ark Biotech
Cambridge, MAVenture Capital-Backed
OVERVIEW
Developer of a fidelity simulation software designed to enhance decision-making from early-stage process development to commercial manufacturing. The company's model-first approach combines biology, chemistry and physics with the predictive power of machine learning and AI, enabling organizations to empower predictive outcomes, optimize processes, and scale with precision, dramatically reducing R&D timelines, cutting costs and increasing accessibility to life-saving therapies and innovative products.
已融资16.88
最新估值54.18
员工数21
成立年份2021
公司概况
- Companies
- Ark Biotech
- Description
- Developer of a fidelity simulation software designed to enhance decision-making from early-stage process development to commercial manufacturing. The company's model-first approach combines biology, chemistry and physics with the predictive power of machine learning and AI, enabling organizations to empower predictive outcomes, optimize processes, and scale with precision, dramatically reducing R&D timelines, cutting costs and increasing accessibility to life-saving therapies and innovative products.
- Website
- www.ark-biotech.com
- HQ Location
- Cambridge, MA
- Year Founded
- 2021
- Keywords
- ai in healthcare, bioprocess optimization, bioprocess platform, bioprocess system, multiphysics modeling, process development, simulation software
- Competitors
- Quartic, DataHow, Basetwo AI, Invert Bio, Eppendorf, Sartorius
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 16.88
- First Financing Date
- 06-Dec-2021
- First Financing Size
- 2.50
- First Financing Valuation
- 9.50
- Last Financing Date
- 14-Aug-2025
- Last Financing Deal Type
- Accelerator/Incubator
- Last Financing Size
- 0.20
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 54.18
- Last Known Valuation Date
- 24-May-2024
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 79.35
- Valuation Estimate Growth Rate
- 46.45%
- Active Investors
- BioTools Innovator, Hawktail, HCVC, Lowercase Capital, Night Capital, Primary Venture Partners, Siddhi Capital, The Engine
- # Active Investors
- 8
- Acquirers
- —
团队与联系人
- Employees
- 21
- Employee Growth %
- 0.00%
- Employee History
- 2026: 21, 2025: 21, 2024: 15, 2023: 12 E, 2022: 8
- Primary Contact
- Yossi Quint
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- yossi@ark-biotech.com
- Primary Contact Phone
- +1 (857) 957-7498
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.00%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 13
- Size Multiple
- 2.63x
- Size Multiple % Change
- -24.27%
- Size Multiple Change
- -0.84x
- Size Multiple Percentile
- 74
- Majestic Referring Domains
- 112
- SimilarWeb Unique Visitors
- 469
- SimilarWeb Unique Visitors Change
- -76
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 6%
- Success Probability Over Time – 3 Year
- 13%
- Success Probability Over Time – 5 Year
- 24%
记录来源：public.companies · 原始序号 #2757 · 所有字段均按数据库原值展示。